12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
Simone Perna,1 Manuela Mainardi,2 Paolo Astrone,2 Carlotta Gozzer,3 Anna Biava,1 Ruben Bacchio,3 Daniele Spadaccini,3 Sebastiano Bruno Solerte,2 Mariangela Rondanelli4 1Department of Biology, College of Science, University of Bahrain, Sakhir Campus, Kingdom of Bahrain; 2University of Pavia, Departme...
Enregistré dans:
Auteurs principaux: | Perna S, Mainardi M, Astrone P, Gozzer C, Biava A, Bacchio R, Spadaccini D, Solerte SB, Rondanelli M |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2018
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c9d8c56def4e472a811b5b030a362e07 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease
par: Nanae Ishida, et autres
Publié: (2021) -
Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs
par: Olga D. Ostroumova, et autres
Publié: (2018) -
Is cancer incidence modified by SGLT2 inhibitors?
par: Lev M. Berstein
Publié: (2019) -
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
par: Aurélie Pahud de Mortanges, et autres
Publié: (2021) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
par: Simes BC, et autres
Publié: (2019)